Bristol Myers Squibb (CELG-RI) EBITDA (2009 - 2026)

Bristol Myers Squibb has disclosed EBITDA across 18 years of filings, most recently posting $2.8 billion for Q1 2026.

• In Q1 2026, EBITDA rose 24.7% year-over-year to $2.8 billion; the TTM figure through Mar 2026 stood at $7.3 billion (up 35.84% YoY), while the FY2025 annual figure was $6.8 billion, up 178.32% from the prior year.
• EBITDA rose to $2.8 billion in Q1 2026, from $1.1 billion in the prior quarter.
• Over the last five years, EBITDA for CELG-RI reached as high as $2.8 billion in Q1 2026 and fell as low as -$11.8 billion in Q1 2024.
• The 5-year median for EBITDA is $1.6 billion (2024), against an average of $884.4 million.
• Annual changes were most pronounced in 2024 — EBITDA slumped 640.92% — and 2025, when it surged 255.96%.
• A 5-year view of EBITDA shows it stood at $1.6 billion in 2022, then dropped by 5.06% to $1.5 billion in 2023, then plunged by 79.89% to $302.0 million in 2024, then surged by 255.96% to $1.1 billion in 2025, then surged by 163.44% to $2.8 billion in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $2.8 billion, $1.1 billion, and $2.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.